Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 1, 2014, Pages 93-100

  Ruiz Ortega, Marta ^a,b,c,d   Ortiz, Alberto ^a,b,c,d   Ramos, Adrian M ^a,b  

^a 28400 Madrid   (Spain)

^b REDINREN   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d IRSIN   (Spain)

Author keywords

chronic kidney disease; cytokine; fibrosis; inflammation; lupus nephritis; TWEAK

Indexed keywords

APOPTOSIS INDUCING FACTOR; APOPTOSOME; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BIOLOGICAL MARKER; BLOCKING ANTIBODY; CD163 ANTIGEN; CXCL16 CHEMOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FURIN; G PROTEIN COUPLED RECEPTOR; GELATINASE B; INTERLEUKIN 17; JANUS KINASE 2; KLOTHO PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; MYOCARDIN; NEUTRALIZING ANTIBODY; QM 56; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANGIOGENESIS; APOPTOSIS; BIOAVAILABILITY; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CELL DAMAGE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; COLLAGEN SYNTHESIS; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DOWN REGULATION; DRUG DELIVERY SYSTEM; ENDOTHELIAL DYSFUNCTION; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROBLAST; HEMODIALYSIS PATIENT; HUMAN; IMMUNE COMPLEX NEPHRITIS; INTERNALIZATION; INTRACELLULAR SIGNALING; KIDNEY CANCER; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE CELL; LIVER REGENERATION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MESANGIUM CELL; NANOMEDICINE; NEPHRITIS; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; PSORIASIS; REGULATORY T LYMPHOCYTE; RENAL PROTECTION; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; TH17 CELL; UPREGULATION; URINARY TRACT OBSTRUCTION; UVEITIS;

ANIMALS; FIBROSIS; HUMANS; INFLAMMATION MEDIATORS; KIDNEY; KIDNEY DISEASES; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTORS; UROLOGICAL AGENTS;

EID: 84890483229     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/01.mnh.0000437331.23794.81     Document Type: Review

References (52)

1. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: Discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008; 7:411-425.
2. Sanz AB, Izquierdo MC, Sanchez-Nino MD, et al. TWEAK and the progression of renal disease: Clinical translation. Nephrol Dial Transplant . (in press). An updated review on the clinical implications of basic research on TWEAK and the kidney with review of ongoing clinical trials targeting TWEAK/Fn14.
3. Blanco-Colio LM, Mart́n-Ventura JL, Carrero JJ, et al. Vascular proteomics and the discovery process of clinical biomarkers: The case of TWEAK. Proteomics Clin Appl 2011; 5:281-288.
4. Gungor O, Kismali E, Sisman AR, et al. The relationships between serum sTWEAK, FGF-23 levels, and carotid atherosclerosis in renal transplant patients. Ren Fail 2013; 35:77-81.
5. Llauradó G, Gonzá lez-Clemente JM, Maymó-Masip E, et al. Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: Relationship with cardiovascular risk factors. A case-control study. PLoS One 2012; 7:e43919.
6. Gungor O, Kircelli F, Asci G, et al. Soluble TWEAK level: Is it a marker for cardiovascular disease in long-term hemodialysis patients J Nephrol 2013; 26:136-143.
7. Carrero JJ, Ortiz A, Qureshi AR, et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:110-118.
8. Dhaun N, Kluth DC. TWEAK: A novel biomarker for lupus nephritis Arthritis Res Ther 2009; 11:133-135.
9. El-Shehaby A, Darweesh H, El-Khatib M, et al. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol 2011; 31:848-856.
10. Brown SA, Ghosh A, Winkles JA. Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kB pathway. J Biol Chem 2010; 285:17432-17441.
11. Fick A, Lang I, Scha fer V, et al. Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14). J Biol Chem 2012; 287:484-495. A complete biochemical study demonstrating that furin cleaves TWEAK and the functional role of Fn14.
12. Maecker H, Varfolomeev E, Kischkel F, et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell 2005; 123:931-944.
13. Willis AL, Tran NL, Chatigny JM, et al. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res 2008; 6:725-734.
14. Moreno JA, Mun oz-Garća B, Mart́n-Ventura JL, et al. The CD163-expressing macrophages recognize and internalize TWEAK: Potential consequences in atherosclerosis. Atherosclerosis 2009; 207:103-110.
15. Burkly LC, Michaelson JS, Zheng TS. TWEAK/Fn14 pathway: An immunological switch for shaping tissue responses. Immunol Rev 2011; 244:99-114.
16. Izquierdo MC, Sanz AB, Mezzano S, et al. TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation. Kidney Int 2012; 81:1098-1107. The first time that TWEAK is shown to regulate a multifunctional protein that may behave as cholesterol scavenger receptor, adhesion molecule and chemokine.
17. Molano A, Lakhani P, Aran A, et al. TWEAK stimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis. Immunol Lett 2009; 125:119-128.
18. Lee SB, Kalluri R. Mechanistic connection between inflammation and fibrosis. Kidney Int 2010; 78 (Suppl. 119):S22-S26.
19. Kitching AR, Holdsworth SR. The emergence of Th17 cells as effectors of renal injury. J Am Soc Nephrol 2011; 22:235-238.
20. Park JS, Park MK, Lee SY, et al. TWEAK promotes the production of interleukin-17 in rheumatoid arthritis. Cytokine 2012; 60:143-149.
21. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2:52ra72.
22. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366:1190-1199.
23. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med 2012; 366:1181-1189.
24. Rodrigues-D́ez R, Rodrigues-D́ez RR, Rayego-Mateos S, et al. The C-terminal module IV of connective tissue growth factor is a novel immune modulator of the Th17 response. Lab Invest 2013; 93:812-824.
25. Jain M, Jakubowski A, Cui L, et al. A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation 2009; 119:2058-2068.
26. Novoyatleva T, Schymura Y, Janssen W, et al. Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction. Basic Res Cardiol 2013; 108:325-337.
27. Chen HN, Wang DJ, Ren MY, et al. TWEAK/Fn14 promotes the proliferation and collagen synthesis of rat cardiac fibroblasts via the NF-kB pathway. Mol Biol Rep 2012; 39:8231-8241.
28. Tirnitz-Parker JE, Viebahn CS, Jakubowski A, et al. Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology 2010; 52:291-302.
29. Kuramitsu K, Sverdlov DY, Liu SB, et al. Failure of fibrotic liver regeneration in mice is linked to a severe fibrogenic response driven by hepatic progenitor cell activation. Am J Pathol 2013; 183:182-194.
30. Hotta K, Sho M, Yamato I, et al. Direct targeting of fibroblast growth factorinducible 14 protein protects against renal ischemia reperfusion injury. Kidney Int 2011; 79:179-188.
31. Xia Y, Campbell SR, Broder A, et al. Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. Clin Immunol 2012; 145:108-121.
32. Ucero AC, Benito-Martin A, Fuentes-Calvo I, et al. TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast. Biochim Biophys Acta 2013; 1832:1744-1755. A recent original study exploring in-depth the role of TWEAK in kidney fibrosis when the insult is persistent and delineating the TWEAK actions on renal fibroblast.
33. Ortiz A, Ucero AC, Egido J. Unravelling fibrosis: Two newcomers and an old foe. Nephrol Dial Transplant 2010; 25:3492-3495.
34. Lebleu VS, Taduri G, O'Connell J, et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med 2013; 19:1047-1053. A recent study demonstrating the role of tubular epithelial cells in renal fibrosis.
35. Campanholle G, Ligresti G, Gharib SA, Duffield JS. Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis. Am J Physiol Cell Physiol 2013; 304:C591-C603.
36. Sakai N, Wada T, Yokoyama H, et al. Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc Natl Acad Sci USA 2006; 103:14098-14103.
37. Sanz AB, Sanchez-Nino MD, Izquierdo MC, et al. TWEAK activates the noncanonical NFkappaB pathway in murine renal tubular cells: Modulation of CCL21. PLoS One 2010; 29:e8955.
38. Moreno JA, Izquierdo MC, Sanchez-Nino MD, et al. The inflammatory cytokines TWEAK and TNFa reduce renal Klotho expression through NFkB. J Am Soc Nephrol 2011; 22:1315-1325.
39. Sanchez-Nino MD, Sanz AB, Ortiz A. Klotho to treat kidney fibrosis. J Am Soc Nephrol 2013; 24:687-689.
40. Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: An international collaborative study. Lancet 1999; 10:93-99.
41. Bonsib SM. Renal cystic diseases and renal neoplasms: A mini-review. Clin J Am Soc Nephrol 2009; 4:1998-2007.
42. Sanz AB, Sanchez-Nino MD, Carrasco S, et al. Inflammatory cytokines and survival factors from serum modulate TWEAK-induced apoptosis in PC-3 prostate cancer cells. PLoS One 2012; 7:e47440. This study explores how altering the tumor cell microenvironment may turn a proliferative response to TWEAK into a lethal signal. It may have application to kidney cancer.
43. Huang M, Narita S, Tsuchiya N, et al. Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome. Carcinogenesis 2011; 32:1589-1596.
44. Michaelson JS, Wisniacki N, Burkly LC, Putterman C. Role of TWEAK in lupus nephritis: A bench-to-bedside review. J Autoimmun 2012; 39:130-142.
45. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003; 2:347-360.
46. Sanchis J, Canal F, Lucas R, Vicent MJ. Polymer drug conjugates for novel molecular targets. Nanomedicine (Lond) 2010; 5:915-935.
47. Vicent MJ, Pé rez-Payá E. Poly-L-glutamic acid (PGA) aided inhibitors of apoptotic protease activating factor 1 (Apaf-1): An antiapoptotic polymeric nanomedicine. J Med Chem 2006; 49:3763-3765.
48. Ucero AC, Berzal S, Ocana-Salceda C, et al. A polymeric nanomedicine diminishes inflammatory events in renal tubular cells. PLoS One 2013; 8:e51992. This study describes the key role of JAK2 in TWEAK-induced inflammation and therapeutic modulation of TWEAK-elicited responses by the nanomolecule QM-56.
49. Flamant M, Bollée G, Hé nique C, Tharaux PL. Epidermal growth factor: A new therapeutic target in glomerular disease. Nephrol Dial Transplant 2012; 27:1297-1304.
50. Rayego-Mateos S, Morgado-Pascual JL, Sanz AB, et al. TWEAK transactivation of the epidermal growth factor receptor mediates renal inflammation. J Pathol 2013; 231:480-494. A recent finding showing a novel mechanism involved in TWEAK-mediated renal inflammation, the activation of the EGFR pathway, which is independent of NF-kB activation.
51. Rousselet E, Traver S, Monnet Y, et al. Tumor necrosis factor-like weak inducer of apoptosis induces astrocyte proliferation through the activation of transforming-growth factor-a/epidermal growth factor receptor signaling pathway. Mol Pharmacol 2012; 82:948-957.
52. Kakiashvili E, Dan Q, Vandermeer M, et al. The epidermal growth factor receptor mediates tumor necrosis factor-alpha-induced activation of the ERK/GEF-H1/RhoA pathway in tubular epithelium. J Biol Chem 2011; 286:9268-9279.